… COVID-19 included severe and critically severe cases. We intended to evaluate all COVID-…
, therefore, VE against symptomatic COVID-19 equals VE against all infections in this study. …

… This study provides the first real world evidence of COVID-19 vaccine effectiveness
against symptomatic COVID-19 in older people in the UK. We find that a single dose of the …

… Polymerase chain reaction testing was performed for symptomatic and asymptomatic patients
(eg, screening for travel or prior to an intervention). The incidence rates of positive SARS-…

… In conclusion, in patients with symptomatic COVID-19, patients fully vaccinated by the
BNT162b2 mRNA or ChAdOx1-S adenovirus vector vaccines had lower frequency of pneumonia …

… The researchers also found BNT162b2 vaccine effectiveness against symptomatic COVID-19
to be 57% after 14–20 days, and 66% after 21–27 days. Although vaccine effectiveness …

… S vaccination induces variant-dependent seroprotective levels for more severe disease,
and this protection is less impacted by neutralization resistance than is symptomatic COVID-19. …

… coronavirus 2 (SARS-CoV-2) has led to the unprecedented pace of development of multiple
vaccines. This review evaluates how adenovirus (Ad) vector … against symptomatic COVID-19 …

… of 76% at preventing symptomatic COVID-19 infection and … It is an adenoviral vector-based
COVID19 vaccine developed … designed with two recombinant adenovirus vectors and was …

… The extremely infectious viral sickness produced by severe acute respiratory coronavirus
syndrome 2 (SARS-CoV-2), coronavirus disease 2019 (COVID-19), has a devastating …

… vector, one used DNA plasmids, and one used inactivated virus. The adenovirus type-5
COVID-… -nCoV had an acceptable efficacy rate at preventing all symptomatic COVID-19 cases. …